Novartis Corporation

1 Health Plz , East Hanover, NJ 07936

Healthcare & Pharmaceuticals - Pharmaceuticals
around $500M - 1B
around 5K - 10K
(862) 778-8300
(479) 464-9092

Novartis provides healthcare solutions that address the evolving needs of patients and societies products to prevent and treat diseases, ease suffering and enhance quality of life. The Novartis portfolio focuses on science-based healthcare sectors that are growing and reward innovation, such as pharmaceuticals, eye care, generics, vaccines and diagnostics, over-the-counter (OTC) and animal health. Novartis is the only company with leading positions in each of these areas. Novartis research is driven by a distinctive clinical and scientific strategy focusing on unmet medical need and knowledge of disease. Corporate social responsibility is an integral part of how Novartis operates and key to our success. We focus on improving access to healthcare globally, and our Malaria Initia... (Source: SEC reports)

Competitor - 1/8
Which company is more competitive with Novartis Corporation?

459 Contacts at this company
Tracy Goodridge
General Manager, Belgium & ...
Gordon Campbell
Chief Procurement Officer
James Steven Fields
Area Business Director
Jeff Conover
Associate Director, Packaging and ...
Richard Kaplan
Global Human Resources Director, …
John Benedetto
Global Head Clinical Operation
Jonathan Graham
Executive Director, US Franchise ?
Claudio Bohorquez
Broker / Owner
J. Michael Ryan
Chief Medical Officer

Aug 21, 2017 21:19:37
EAST HANOVER, N.J., Aug. 21, 2017 /PRNewswire/ -- Novartis announced today the launch of a mobile research study for people with multiple sclerosis (MS) that collects data via their smartphone, [...]

Jul 12, 2017 21:37:03
EAST HANOVER, N.J., July 12, 2017 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisagenlecleucel), [...]

Jun 23, 2017 21:36:37
EAST HANOVER, N.J., June 23, 2017 /PRNewswire/ -- Novartis today announced updated results from the ELIANA clinical trial demonstrating CTL019 (tisagenlecleucel) remission rates are maintained at six months in relapsed/refractory (r/r) [...]

Jun 7, 2017 21:36:48
EAST HANOVER, N.J., June 7, 2017 /PRNewswire/ -- Novartis announced findings from an interim analysis of its multi-center Phase II JULIET study (NCT02445248) of CTL019 (tisagenlecleucel) in adult patients with relapsed [...]

Jun 5, 2017 21:36:54
EAST HANOVER, N.J. , June 5, 2017 /PRNewswire/ -- Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and [...]

Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.